General Information of Drug (ID: DMGYK2N)

Drug Name
Tilsotolimod Drug Info
Synonyms IMO-2125
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMGYK2N

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Toll-like receptor 9 (TLR9) TTSHG0T TLR9_HUMAN Agonist [2]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Melanoma
ICD Disease Classification 2C30
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Toll-like receptor 9 (TLR9) DTT TLR9 2.58E-01 -0.06 -0.17
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03445533) A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301) (ILLUMINATE-301). U.S. National Institutes of Health.
2 Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma. Cancer Discov. 2021 Mar 11;candisc.1546.2020.